Cerliponase Alfa
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Conditions
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Trial Timeline
Aug 19, 2020 → Aug 31, 2030
NCT ID
NCT04476862About Cerliponase Alfa
Cerliponase Alfa is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2. The current trial status is active. This product is registered under clinical trial identifier NCT04476862. Target conditions include Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04476862 | Pre-clinical | Active |